PMV Pharmaceuticals
PMVP
65 hedge funds and large institutions have $46.8M invested in PMV Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 10 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 18
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
2% more funds holding
Funds holding: 64 → 65 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.43% less ownership
Funds ownership: 70.75% → 70.33% (-0.43%)
2% less capital inflows, than outflows
Capital inflows: $3.22M | Capital outflows: $3.28M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$611K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$610K |
| 3 |
Two Sigma Investments
New York
|
+$585K |
| 4 |
Tang Capital Management
San Diego,
California
|
+$207K |
| 5 |
Jane Street
New York
|
+$156K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$1.34M |
| 2 |
Stonepine Capital Management
Bend,
Oregon
|
-$294K |
| 3 |
Peapod Lane Capital
Bedford Hills,
New York
|
-$284K |
| 4 |
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$283K |
| 5 |
Boothbay Fund Management
New York
|
-$234K |
PMVP Hedge Fund Activity: Q4 2025 in Review
65 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q4 2025, worth a combined $46.8M — down 11% from $52.5M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PMVP positions and 10 closed out — a net gain of 2 holders — while 22 added to existing stakes and 18 trimmed.
The largest buyer was Two Sigma Advisers, adding an estimated $611K. The largest seller was OrbiMed, cutting an estimated $1.34M.
- 65 institutional investors held PMV Pharmaceuticals (PMVP) as of Q4 2025, up from 64 in Q3 2025.
- Funds reported $46.8M of PMV Pharmaceuticals stock for Q4 2025, down 11% quarter-over-quarter.
- 12 funds opened new PMV Pharmaceuticals positions in Q4 2025 and 10 closed out, a net change of +2 holders.
- The largest PMV Pharmaceuticals buyer in Q4 2025 was Two Sigma Advisers, an estimated $611K added.
- The largest PMV Pharmaceuticals seller in Q4 2025 was OrbiMed, an estimated $1.34M sold.
Based on aggregated 13F filings for Q4 2025.